Myriad Pharma (MYRX) Identifies IKK Epsilon as an IND to Potentially Fight Cancer, Obesity, and Diabetes
More News related to MYRX
- Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
- Piper Jaffray Upgrades Myriad Pharmaceuticals (MYRX) to Neutral
- Morning Movers 11/18: ABK, CHS, LDK, RDN Higher; ONCY, NANO, EXEL, ADSK, CNQR Lower
- Myriad Pharma (MYRX) Presents Initial Phase 2a Data for Azixa
- Initial Phase 2 Results for Myriad Pharmaceuticals' Azixa(TM) (MPC-6827) in Metastatic Melanoma
Myriad Pharmaceuticals, Inc. (Nasdaq: MYRX) today announced the identification of an Investigational New Drug (IND) candidate targeting a novel molecular target, the protein kinase IKK epsilon.
A recent publication in the September issue of Cell from the laboratory of Dr. Alan Saltiel (Chiang et al, (2009) Cell 138, 961-975) identified IKK epsilon as a central regulator of chronic inflammation, obesity and diabetes. Based upon that Cell paper, inhibitors of IKK epsilon are expected to have significant potential for the treatment of obesity, diabetes and associated diseases.
Myriad Pharmaceuticals' IKK epsilon program was originally launched to exploit the potential of IKK epsilon as a novel oncology target. Published reports and internal research at Myriad Pharmaceuticals have demonstrated that IKK epsilon expression is amplified in human breast, ovarian, and prostate tumor cells. Overexpression of IKK epsilon transforms cells in culture and conversely, reduction of IKK epsilon expression or inhibition of activity inhibits tumor cell growth.
Related Categories
Corporate NewsStocks Mentioned
-0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
